$ZVRA

Watton Corey Michael sold $138K of ZVRA

Watton Corey Michael sold 12,300 shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $11.25 ($0.14M total) on 2026-08-10.

Original reporting
SEC EDGAR · Watton Corey Michael
Published Aug 12, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ZVRA
Neutral
medium confidence
Mentioned
$ZVRA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZVRANeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 12,300 shares at $11.2502 on 2026-08-10, with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but there is no new operational or financial catalyst in the text.

03

What to watch

The filing shows holdings after sale (1,800 shares) but provides no context on total compensation, prior sale cadence, or whether other insiders also sold around the same time.

Relevance 4/10Novelty 3/10Timing: filed after-hours on 2026-08-12, reflecting a sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for ZEVRA THERAPEUTICS, INC.

Company-level read

Ticker impact

$ZVRANeutralMedium confidence
Context

Zevra Therapeutics director Watton Corey Michael sold 12,300 shares in an open-market transaction for about $138,377 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction details but no accompanying guidance, results, or operational change.

Market effects

No clear sector read-through from a single director open-market sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply negative information; sales can be driven by diversification, taxes, or pre-existing personal liquidity needs.

Key entities

  • Zevra Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Watton Corey Michael

    Director who sold 12,300 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZVRAMed

Zevra Therapeutics Q2 Earnings Call Highlights

Zevra Therapeutics (NASDAQ:ZVRA) reported Q2 updates on MIPLYFFA, including high refill, compliance and persistence, and payer coverage of 69% of covered lives. Net reimbursements were $9 million. In the EU, Zevra will re-examine arimoclomol after a CHMP negative opinion, with an expected Q4 decision. Cash was $260.2 million.

$ZVRAMed

ZEVRA THERAPEUTICS, INC. (ZVRA): Results of Operations and Financial Condition

ZEVRA THERAPEUTICS, INC. (ZVRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zvra-20260805xex991earnings.htm EX-99.1 Document Exhibit 99.1 Zevra Reports Second Quarter 2026 Financial Results and Corporate Update $39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025

$ZVRAMedAI 8/10

Zevra Slips on Revealing Opinion on Treatment

Zevra Therapeutics (NASDAQ: ZVRA) fell after the EMA CHMP issued a negative opinion on its marketing authorization application for arimoclomol to treat Niemann-Pick disease type C. Zevra said it will request a re-examination and provide supporting explanations, and it continues expanded access to support eligible patients and gather real-world evidence.

$ZVRAMed

Zevra Therapeutics extends MIPLYFFA exclusivity to 2041

Zevra Therapeutics said it filed a patent for MIPLYFFA (arimoclomol) to be listed in the FDA’s Orange Book, with protection extending to 2041. The company said the Orange Book listing would strengthen MIPLYFFA’s exclusivity and could trigger an automatic stay on generic approvals if challenged. Zevra shares rose more than 9.5% on Monday.